In ₹ Crore except Per Share Latest Annual	SYNGENE FY26	SAILIFE FY26	DIVISLAB FY26	WOCKPHARMA FY26	Peer Average
Valuation — at last close
P/E	◆ 50.65×	89.94×	99.89×	146.56×	112.13× -55%
P/B	◆ 3.32×	12.75×	15.28×	6.31×	11.45× -71%
EV/EBITDA	◆ 16.09×	50.09×	73.43×	50.54×	58.02× -72%
Market Cap	₹16,060 Cr	₹31,676 Cr	₹2.56L Cr	₹31,151 Cr	₹1.06L Cr -85%
Growth
Revenue CAGR 3Y	5.40%	—	◆ 10.78%	8.36%	9.57% -44%
Revenue CAGR 5Y	◆ 11.35%	—	8.67%	4.49%	6.58% +72%
Net Income CAGR 3Y	-11.98%	—	◆ 12.09%	—	12.09% -199%
Revenue YoY (latest Q)	-8.55%	11.66%	◆ 27.80%	25.88%	21.78% -139%
Net Income YoY (latest Q)	-52.01%	21.22%	65.50%	◆ 199.07%	95.26% -155%
Profitability
EBITDA Margin	24.57%	28.79%	◆ 32.59%	19.33%	26.90% -9%
Net Income Margin	8.47%	15.91%	◆ 24.32%	5.90%	15.38% -45%
Return on Common Equity	6.62%	15.13%	◆ 16.19%	4.58%	11.97% -45%
Return on Capital Employed	8.54%	17.79%	◆ 17.80%	6.50%	14.03% -39%
Return on Assets	4.57%	10.28%	◆ 13.89%	2.38%	8.85% -48%
Credit & Quality
Total Debt/Equity	◆ 0.00×	0.04×	0.00×	0.40×	0.15× -100%
Interest Coverage	9.54×	11.83×	◆ 129.48×	2.00×	47.77× -80%
Scale — latest FY
Revenue / Total Income	₹3,739 Cr	₹2,192 Cr	₹10,560 Cr	₹3,373 Cr	₹5,375 Cr -30%
Net Income	₹317 Cr	₹349 Cr	₹2,568 Cr	₹199 Cr	₹1,039 Cr -70%
Total Assets	₹7,055 Cr	₹3,626 Cr	₹20,033 Cr	₹8,615 Cr	₹10,758 Cr -34%
EPS	₹7.87	₹16.63	₹96.75	₹13.12	₹42.17 -81%
Book Value per Share	₹120.11	₹117.28	₹632.49	₹304.94	₹351.57 -66%

◆ best value in the comp set per metric · Δ = subject vs average of the other companies.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.